NCT03861234View on ClinicalTrials.gov

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 27, 2019

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2023

Conditions
Wet Macular Degeneration
Interventions
DRUG

BI 836880

Solution for Intravitreal (IVT) injection

Trial Locations (14)

10003

New York Eye and Ear Infirmary of Mount Sinai, New York

12200

Charité - Universitätsmedizin Berlin, Berlin

16507

Erie Retina Research, LLC, Erie

37075

Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen

77401

Retina Consultants of Texas, Bellaire

78750

Austin Clinical Research, LLC, Austin

79606

Retina Research Institute of Texas, Abilene

85020

Associated Retina Consultants, Ltd., Phoenix

89075

Universitätsklinikum Ulm, Ulm

97401

Verum Research, LLC, Eugene

BS1 2LX

Bristol Eye Hospital, Bristol

L7 8XP

Royal Liverpool University Hospital, Liverpool

EC1V 2PD

Moorfields Eye Hospital, London

SR2 9HP

Sunderland Eye Infirmary, Sunderland

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03861234 - A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD) | Biotech Hunter | Biotech Hunter